Recombinant Platelet Factor 4: A Therapeutic, Anti-Neoplastic Chimera?

 

 Buy Article Permissions and Reprints

ABSTRACT

Angiogenesis plays a pivotal role in many serious and life-threatening disorders (e.g., cancer, atherosclerosis, diabetes, arthritis, psoriasis, nephropathy, and retinopathy) and is regulated by a delicate equilibrium between a variety of pro- and anti-angiogenic factors. Although recombinant platelet factor 4 (PF4) was originally developed and evaluated as a clinical alternative to protamine for heparin neutralization, the current scientific evidence supports a role for this protein and derivative peptides in inhibiting tumor growth and spread, by suppression of tumor-induced neovascularization in many different types of solid tumors. As a heparin-binding tetramer, recombinant PF4 interferes with several steps of endothelial cell proliferation, migration, and angiogenesis, regulates apoptotic death through activation of distinct signal transduction pathways, inhibits growth factor receptor binding, amplifies the inflammatory response of natural killer cells through regulation of cytokines production, and induces and maintains a nonspecific immune response to cancer cells. These biological evidences paved the way for the development and marketing of novel PF4-based angiostatic agents characterized by reduced toxicity and improved bioavailability, thus raising the possibility of an alternative approach for preventing and treating growth and metastasis of tumors. Some PF4-derived molecules such as carboxyl-terminal fragments of recombinant human PF4 and modified and chimeric peptides have already been developed that exhibit stronger anti-angiogenic properties than the parent molecule and may serve as leads for further therapeutic developments. Newer means of delivering of this anti-angiogenic agent are also being attempted, including PF4-bearing polymeric microspheres, vector-mediated PF4 transduction, transgene transfection into oncolytic viruses, and molecular targeting therapy against PF4 and rHuPF4 conjugates. These delivery systems aim to produce high concentrations of the therapeutic agent in a local area for a sustained period, thereby avoiding the typical problems encountered with long-term administration of recombinant proteins.

REFERENCES

• 1 Sachais B S, Higazi A A, Cines D B, Poncz M, Kowalska M A. Interactions of platelet factor 4 with the vessel wall.  Semin Thromb Hemost. 2004;  30(3) 351-358
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Deuel T F, Keim P S, Farmer M, Heinrikson R L. Amino acid sequence of human platelet factor 4.  Proc Natl Acad Sci U S A. 1977;  74(6) 2256-2258
  CrossrefPubMedGoogle Scholar
• 3 Walz D A, Wu V Y, de Lamo R, Dene H, McCoy L E. Primary structure of human platelet factor 4.  Thromb Res. 1977;  11(6) 893-898
  CrossrefPubMedGoogle Scholar
• 4 Hermodson M, Schmer G, Kurachi K. Isolation, crystallization, and primary amino acid sequence of human platelet factor 4.  J Biol Chem. 1977;  252(18) 6276-6279
  PubMedGoogle Scholar
• 5 Eisman R, Surrey S, Ramachandran B, Schwartz E, Poncz M. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt.  Blood. 1990;  76(2) 336-344
  PubMedGoogle Scholar
• 6 Zhang X, Chen L, Bancroft D P, Lai C K, Maione T E. Crystal structure of recombinant human platelet factor 4.  Biochemistry. 1994;  33(27) 8361-8366
  CrossrefPubMedGoogle Scholar
• 7 Griffin C A, Emanuel B S, LaRocco P, Schwartz E, Poncz M. Human platelet factor 4 gene is mapped to 4q12----q21.  Cytogenet Cell Genet. 1987;  45(2) 67-69
  CrossrefPubMedGoogle Scholar
• 8 Poncz M, Surrey S, LaRocco P et al.. Cloning and characterization of platelet factor 4 cDNA derived from a human erythroleukemic cell line.  Blood. 1987;  69(1) 219-223
  PubMedGoogle Scholar
• 9 Van Damme J, Van Beeumen J, Opdenakker G, Billiau A. A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity.  J Exp Med. 1988;  167(4) 1364-1376
  CrossrefPubMedGoogle Scholar
• 10 Briquet-Laugier V, Lavenu-Bombled C, Schmitt A et al.. Probing platelet factor 4 alpha-granule targeting.  J Thromb Haemost. 2004;  2(12) 2231-2240
  CrossrefPubMedGoogle Scholar
• 11 Eslin D E, Zhang C, Samuels K J et al.. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin.  Blood. 2004;  104(10) 3173-3180
  CrossrefPubMedGoogle Scholar
• 12 Schaffner A, Rhyn P, Schoedon G, Schaer D J. Regulated expression of platelet factor 4 in human monocytes—role of PARs as a quantitatively important monocyte activation pathway.  J Leukoc Biol. 2005;  78(1) 202-209
  CrossrefPubMedGoogle Scholar
• 13 Maier M, Wutzler S, Bauer M, Trendafilov P, Henrich D, Marzi I. Altered gene expression patterns in dendritic cells after severe trauma: implications for systemic inflammation and organ injury.  Shock. 2008;  30(4) 344-351
  CrossrefPubMedGoogle Scholar
• 14 Maier M, Geiger E V, Henrich D et al.. Platelet factor 4 is highly upregulated in dendritic cells after severe trauma.  Mol Med. 2009;  15(11–12) 384-391
  PubMedGoogle Scholar
• 15 Gewirtz A M, Zhang J, Ratajczak J et al.. Chemokine regulation of human megakaryocytopoiesis.  Blood. 1995;  86(7) 2559-2567
  PubMedGoogle Scholar
• 16 Maurer A M, Zhou B, Han Z C. Roles of platelet factor 4 in hematopoiesis and angiogenesis.  Growth Factors. 2006;  24(4) 242-252
  CrossrefPubMedGoogle Scholar
• 17 Lambert M P, Rauova L, Bailey M, Sola-Visner M C, Kowalska M A, Poncz M. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.  Blood. 2007;  110(4) 1153-1160
  CrossrefPubMedGoogle Scholar
• 18 Lambert M P, Wang Y, Bdeir K H, Nguyen Y, Kowalska M A, Poncz M. Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes.  Blood. 2009;  114(11) 2290-2298
  CrossrefPubMedGoogle Scholar
• 19 Amelot A A, Tagzirt M, Ducouret G, Kuen R L, Le Bonniec B F. Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin.  J Biol Chem. 2007;  282(1) 710-720
  CrossrefPubMedGoogle Scholar
• 20 Dudek A Z, Pennell C A, Decker T D, Young T A, Key N S, Slungaard A. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C.  J Biol Chem. 1997;  272(50) 31785-31792
  CrossrefPubMedGoogle Scholar
• 21 Preston R J, Tran S, Johnson J A et al.. Platelet factor 4 impairs the anticoagulant activity of activated protein C.  J Biol Chem. 2009;  284(9) 5869-5875
  CrossrefPubMedGoogle Scholar
• 22 Mosnier L O, Bouma B N, Griffin J H. Platelet factor 4 upregulates protein C activation relative to TAFI activation. Paper presented at: XIX Congress of The International Society on Thrombosis and Haemostasis 2003 OC376 Birmingham, United Kingdom;
  PubMedGoogle Scholar
• 23 Sachais B S, Kuo A, Nassar T et al.. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface.  Blood. 2002;  99(10) 3613-3622
  CrossrefPubMedGoogle Scholar
• 24 Nassar T, Sachais B S, Akkawi S et al.. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells.  J Biol Chem. 2003;  278(8) 6187-6193
  CrossrefPubMedGoogle Scholar
• 25 Pitsilos S, Hunt J, Mohler E R et al.. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters.  Thromb Haemost. 2003;  90(6) 1112-1120
  PubMedGoogle Scholar
• 26 Kaiser P, Harenberg J, Walenga J M et al.. Effects of a heparin-binding protein on blood coagulation and platelet function.  Semin Thromb Hemost. 2001;  27(5) 495-502
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Mixon T A, Dehmer G J. Recombinant platelet factor 4 for heparin neutralization.  Semin Thromb Hemost. 2004;  30(3) 369-377
  Article in Thieme ConnectPubMedGoogle Scholar
• 28 Deuel T F, Senior R M, Chang D, Griffin G L, Heinrikson R L, Kaiser E T. Platelet factor 4 is chemotactic for neutrophils and monocytes.  Proc Natl Acad Sci U S A. 1981;  78(7) 4584-4587
  CrossrefPubMedGoogle Scholar
• 29 Martí F, Bertran E, Llucià M et al.. Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8.  J Leukoc Biol. 2002;  72(3) 590-597
  PubMedGoogle Scholar
• 30 Pervushina O, Scheuerer B, Reiling N et al.. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients.  J Immunol. 2004;  173(3) 2060-2067
  PubMedGoogle Scholar
• 31 Liu C Y, Battaglia M, Lee S H, Sun Q H, Aster R H, Visentin G P. Platelet factor 4 differentially modulates CD4+CD25+(regulatory) versus CD4+CD25- (nonregulatory) T cells.  J Immunol. 2005;  174(5) 2680-2686
  PubMedGoogle Scholar
• 32 Scheuerer B, Ernst M, Dürrbaum-Landmann I et al.. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages.  Blood. 2000;  95(4) 1158-1166
  PubMedGoogle Scholar
• 33 Xia C Q, Kao K J. Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cells.  Int Immunol. 2003;  15(8) 1007-1015
  CrossrefPubMedGoogle Scholar
• 34 Xiao Z, Visentin G P, Dayananda K M, Neelamegham S. Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.  Blood. 2008;  112(4) 1091-1100
  CrossrefPubMedGoogle Scholar
• 35 Kaplan K L, Broekman M J, Chernoff A, Lesznik G R, Drillings M. Platelet alpha-granule proteins: studies on release and subcellular localization.  Blood. 1979;  53(4) 604-618
  CrossrefPubMedGoogle Scholar
• 36 Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review.  Semin Thromb Hemost. 2006;  32(8) 803-809
  Article in Thieme ConnectPubMedGoogle Scholar
• 37 Kannan M, Saxena R, Adiguzel C, Fareed J. An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients.  Semin Thromb Hemost. 2009;  35(3) 337-343
  Article in Thieme ConnectPubMedGoogle Scholar
• 38 Mattioli A V. Prevalence of anti-PF4/heparin antibodies and the HIT syndrome in cardiovascular medicine.  Semin Thromb Hemost. 2004;  30(3) 291-295
  Article in Thieme ConnectPubMedGoogle Scholar
• 39 McKenzie S E, Reilly M P. Heparin-induced thrombocytopenia and other immune thrombocytopenias: lessons from mouse models.  Semin Thromb Hemost. 2004;  30(5) 559-568
  Article in Thieme ConnectPubMedGoogle Scholar
• 40 Prechel M, Walenga J M. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.  Semin Thromb Hemost. 2008;  34(1) 86-96
  Article in Thieme ConnectPubMedGoogle Scholar
• 41 Walenga J M, Jeske W P, Prechel M M, Bacher P, Bakhos M. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs.  Semin Thromb Hemost. 2004;  30(Suppl 1) 69-80
  Article in Thieme ConnectPubMedGoogle Scholar
• 42 Walenga J M, Jeske W P, Prechel M M, Bakhos M. Newer insights on the mechanism of heparin-induced thrombocytopenia.  Semin Thromb Hemost. 2004;  30(Suppl 1) 57-67
  Article in Thieme ConnectPubMedGoogle Scholar
• 43 Warkentin T E. An overview of the heparin-induced thrombocytopenia syndrome.  Semin Thromb Hemost. 2004;  30(3) 273-283
  Article in Thieme ConnectPubMedGoogle Scholar
• 44 Suvarna S, Qi R, Arepally G M. Optimization of a murine immunization model for study of PF4/heparin antibodies.  J Thromb Haemost. 2009;  7(5) 857-864
  CrossrefPubMedGoogle Scholar
• 45 Rauova L, Zhai L, Kowalska M A, Arepally G M, Cines D B, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.  Blood. 2006;  107(6) 2346-2353
  CrossrefPubMedGoogle Scholar
• 46 Suvarna S, Espinasse B, Qi R et al.. Determinants of PF4/heparin immunogenicity.  Blood. 2007;  110(13) 4253-4260
  CrossrefPubMedGoogle Scholar
• 47 Lambert M P, Rauova L, Bailey M, Sola-Visner M C, Kowalska M A, Poncz M. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.  Blood. 2007;  110(4) 1153-1160
  CrossrefPubMedGoogle Scholar
• 48 Francis J L. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex.  Semin Thromb Hemost. 2004;  30(3) 359-368
  Article in Thieme ConnectPubMedGoogle Scholar
• 49 Wojtukiewicz M Z, Sierko E, Kisiel W. The role of hemostatic system inhibitors in malignancy.  Semin Thromb Hemost. 2007;  33(7) 621-642
  Article in Thieme ConnectPubMedGoogle Scholar
• 50 Wojtukiewicz M Z, Sierko E. Inhibitors of hemostatic system in cancer: basic and clinical aspects.  Semin Thromb Hemost. 2007;  33 619-620
  Article in Thieme ConnectPubMedGoogle Scholar
• 51 Sierko E, Wojtukiewicz M Z, Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology.  Semin Thromb Hemost. 2007;  33(7) 653-659
  Article in Thieme ConnectPubMedGoogle Scholar
• 52 Amirkhosravi A, Meyer T, Amaya M et al.. The role of tissue factor pathway inhibitor in tumor growth and metastasis.  Semin Thromb Hemost. 2007;  33(7) 643-652
  Article in Thieme ConnectPubMedGoogle Scholar
• 53 O'Reilly M S. Antiangiogenic antithrombin.  Semin Thromb Hemost. 2007;  33(7) 660-666
  Article in Thieme ConnectPubMedGoogle Scholar
• 54 Hanly A M, Winter D C. The role of thrombomodulin in malignancy.  Semin Thromb Hemost. 2007;  33(7) 673-679
  Article in Thieme ConnectPubMedGoogle Scholar
• 55 Tsopanoglou N E, Maragoudakis M E. Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.  Semin Thromb Hemost. 2007;  33(7) 680-687
  Article in Thieme ConnectPubMedGoogle Scholar
• 56 Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination.  Semin Thromb Hemost. 2007;  33(7) 688-694
  Article in Thieme ConnectPubMedGoogle Scholar
• 57 Weitz I C, Liebman H A. The role of oral anticoagulants in tumor biology.  Semin Thromb Hemost. 2007;  33(7) 695-698
  Article in Thieme ConnectPubMedGoogle Scholar
• 58 Sierko E, Wojtukiewicz M Z. Inhibition of platelet function: does it offer a chance of better cancer progression control?.  Semin Thromb Hemost. 2007;  33(7) 712-721
  Article in Thieme ConnectPubMedGoogle Scholar
• 59 Snyder K M, Kessler C M. The pivotal role of thrombin in cancer biology and tumorigenesis.  Semin Thromb Hemost. 2008;  34(8) 734-741
  Article in Thieme ConnectPubMedGoogle Scholar
• 60 Lippi G, Franchini M, Salvagno G L, Guidi G C. Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency.  Cancer Treat Rev. 2007;  33(5) 427-436
  CrossrefPubMedGoogle Scholar
• 61 Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer.  J Thromb Thrombolysis. 2007;  24(1) 29-38
  CrossrefPubMedGoogle Scholar
• 62 Pandya N M, Dhalla N S, Santani D D. Angiogenesis—a new target for future therapy.  Vascul Pharmacol. 2006;  44(5) 265-274
  CrossrefPubMedGoogle Scholar
• 63 Gupta K, Zhang J. Angiogenesis: a curse or cure?.  Postgrad Med J. 2005;  81(954) 236-242
  CrossrefPubMedGoogle Scholar
• 64 Park K S, Rifat S, Eck H, Adachi K, Surrey S, Poncz M. Biologic and biochemic properties of recombinant platelet factor 4 demonstrate identity with the native protein.  Blood. 1990;  75(6) 1290-1295
  PubMedGoogle Scholar
• 65 Maione T E, Gray G S, Petro J et al.. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.  Science. 1990;  247(4938) 77-79
  CrossrefPubMedGoogle Scholar
• 66 Sharpe R J, Byers H R, Scott C F, Bauer S I, Maione T E. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4.  J Natl Cancer Inst. 1990;  82(10) 848-853
  CrossrefPubMedGoogle Scholar
• 67 Maione T E, Gray G S, Hunt A J, Sharpe R J. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity.  Cancer Res. 1991;  51(8) 2077-2083
  PubMedGoogle Scholar
• 68 Tatakis D N. Human platelet factor 4 is a direct inhibitor of human osteoblast-like osteosarcoma cell growth.  Biochem Biophys Res Commun. 1992;  187(1) 287-293
  CrossrefPubMedGoogle Scholar
• 69 Han Z C, Maurer A M, Bellucci S et al.. Inhibitory effect of platelet factor 4 (PF4) on the growth of human erythroleukemia cells: proposed mechanism of action of PF4.  J Lab Clin Med. 1992;  120(4) 645-660
  PubMedGoogle Scholar
• 70 Kolber D L, Knisely T L, Maione T E. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.  J Natl Cancer Inst. 1995;  87(4) 304-309
  CrossrefPubMedGoogle Scholar
• 71 Yoshimitsu K, Wright K C, Wallace S, Charnsangavej C, Mavligit G M. Hepatic arterial infusion of recombinant platelet factor-4 suppresses metastases to the lungs from tumors implanted into the livers of rabbits.  Cancer. 1995;  75(10) 2435-2441
  CrossrefPubMedGoogle Scholar
• 72 Belman N, Bonnem E M, Harvey H A, Lipton A. Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma.  Invest New Drugs. 1996;  14(4) 387-389
  PubMedGoogle Scholar
• 73 Tanaka T, Manome Y, Wen P, Kufe D W, Fine H A. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.  Nat Med. 1997;  3(4) 437-442
  CrossrefPubMedGoogle Scholar
• 74 Li Y, Liu Y, Jin Y et al.. Transfer of cDNAs of platelet factor 4 and N-truncated peptide inhibits solid tumor growth in vivo [in Chinese].  Zhonghua Yi Xue Za Zhi (Taipei). 2002;  82(1) 35-38
  PubMedGoogle Scholar
• 75 Li Y, Jin Y, Chen H et al.. Suppression of tumor growth by viral vector-mediated gene transfer of N-terminal truncated platelet factor 4.  Cancer Biother Radiopharm. 2003;  18(5) 829-840
  CrossrefPubMedGoogle Scholar
• 76 Wu L H, Song G L, Diao S Y et al.. Inhibition of tumor angiogenesis in nude mice by adenovirus-mediated PF4 p17-70 cDNA transfection [in Chinese].  Zhonghua Xue Ye Xue Za Zhi. 2003;  24(8) 426-429
  PubMedGoogle Scholar
• 77 Bello L, Giussani C, Carrabba G et al.. Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors.  Clin Cancer Res. 2002;  8(11) 3539-3548
  PubMedGoogle Scholar
• 78 Benny O, Duvshani-Eshet M, Cargioli T et al.. Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth.  Clin Cancer Res. 2005;  11(2 Pt 1) 768-776
  PubMedGoogle Scholar
• 79 Benny O, Kim S K, Gvili K et al.. In vivo fate and therapeutic efficacy of PF-4/CTF microspheres in an orthotopic human glioblastoma model.  FASEB J. 2008;  22(2) 488-499
  CrossrefPubMedGoogle Scholar
• 80 Yamaguchi K, Ogawa K, Katsube T et al.. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis.  Anticancer Res. 2005;  25(2A) 847-851
  PubMedGoogle Scholar
• 81 Liu T C, Zhang T, Fukuhara H et al.. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.  Mol Ther. 2006;  14(6) 789-797
  CrossrefPubMedGoogle Scholar
• 82 Struyf S, Burdick M D, Proost P, Van Damme J, Strieter R M. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis.  Circ Res. 2004;  95(9) 855-857
  CrossrefPubMedGoogle Scholar
• 83 Struyf S, Burdick M D, Peeters E et al.. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis.  Cancer Res. 2007;  67(12) 5940-5948
  CrossrefPubMedGoogle Scholar
• 84 Vandercappellen J, Noppen S, Verbeke H et al.. Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells.  J Leukoc Biol. 2007;  82(6) 1519-1530
  CrossrefPubMedGoogle Scholar
• 85 Li X, Jiang L, Wang Y et al.. Inhibition of angiogenesis by a novel small peptide consisting of the active fragments of platelet factor-4 and vasostatin.  Cancer Lett. 2007;  256(1) 29-32
  CrossrefPubMedGoogle Scholar
• 86 Borgström P, Discipio R, Maione T E. Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma.  Anticancer Res. 1998;  18(6A) 4035-4041
  PubMedGoogle Scholar
• 87 Cheng S H, Ng M H, Lau K M et al.. 4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4.  Blood. 2007;  109(5) 2089-2099
  CrossrefPubMedGoogle Scholar
• 88 Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis.  Semin Thromb Hemost. 2004;  30(3) 379-385
  Article in Thieme ConnectPubMedGoogle Scholar
• 89 Jouan V, Canron X, Alemany M et al.. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action.  Blood. 1999;  94(3) 984-993
  PubMedGoogle Scholar
• 90 Liu Y J, Lu S H, Han Z C. Signal transduction of chemokine platelet factor 4 in human erythroleukemia cells.  Int J Hematol. 2002;  75(4) 401-406
  CrossrefPubMedGoogle Scholar
• 91 Lasagni L, Francalanci M, Annunziato F et al.. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.  J Exp Med. 2003;  197(11) 1537-1549
  CrossrefPubMedGoogle Scholar
• 92 Bikfalvi A, Gimenez-Gallego G. The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules.  Semin Thromb Hemost. 2004;  30(1) 137-144
  Article in Thieme ConnectPubMedGoogle Scholar
• 93 Sulpice E, Contreres J O, Lacour J, Bryckaert M, Tobelem G. Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms.  Eur J Biochem. 2004;  271(16) 3310-3318
  CrossrefPubMedGoogle Scholar
• 94 Perollet C, Han Z C, Savona C, Caen J P, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization.  Blood. 1998;  91(9) 3289-3299
  PubMedGoogle Scholar
• 95 Peng H, Wen T C, Igase K et al.. Suppression by platelet factor 4 of the myogenic activity of basic fibroblast growth factor.  Arch Histol Cytol. 1997;  60(2) 163-174
  CrossrefPubMedGoogle Scholar
• 96 Slungaard A. Platelet factor 4: a chemokine enigma.  Int J Biochem Cell Biol. 2005;  37(6) 1162-1167
  CrossrefPubMedGoogle Scholar
• 97 Griffioen A W, Damen C A, Mayo K H et al.. Angiogenesis inhibitors overcome tumor induced endothelial cell anergy.  Int J Cancer. 1999;  80(2) 315-319
  CrossrefPubMedGoogle Scholar
• 98 Martí F, Bertran E, Llucià M et al.. Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8.  J Leukoc Biol. 2002;  72(3) 590-597
  PubMedGoogle Scholar
• 99 Airoldi I, Cocco C, Giuliani N et al.. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.  Blood. 2008;  112(3) 750-759
  CrossrefPubMedGoogle Scholar
• 100 Hagedorn M, Zilberberg L, Lozano R M et al.. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2.  FASEB J. 2001;  15(3) 550-552
  PubMedGoogle Scholar
• 101 Hagedorn M, Zilberberg L, Wilting J et al.. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.  Cancer Res. 2002;  62(23) 6884-6890
  PubMedGoogle Scholar
• 102 Dymicka-Piekarska V, Butkiewicz A, Kemona H, Gryko M, Mantur M. Does colorectal cancer clinical advancement and surgical treatment affect platelet factor 4 concentration [in Polish].  Pol Merkuriusz Lek. 2004;  17(102) 575-578
  PubMedGoogle Scholar

Prof. Giuseppe LippiM.D. 

U.O. Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma

Strada Abbeveratoia 2/a, 43100 - Parma, Italy

Email: giuseppe.lippi@univr.it

Email: ulippi@tin.it

Email: glippi@ao.pr.it